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auxiliary subunits (α 2 δ 1-4 , β [1] [2] [3] [4] and γ [1] [2] [3] [4] [5] [6] [7] [8] (Fig. 1) . Ten different Ca v -α 1 subunits have been characterized which can be classified based on their electrophysiological and pharmacological properties into high-voltage activated (HVA) and low-voltage activated (LVA) Ca 2+ channels. HVA Ca 2+ channels are further grouped into dihydropyridine (DHP)-sensitive L ("long-lasting")-type Ca v 1.1-1.4 and non-L-type Ca v 2.1-2.3 channels which are less DHP-sensitive. The LVA T-("transient/tiny") type Ca 2+ channels include Ca v 3.1-3.3 [4, 9, 10] . The latter channels are characterized by rather negative membrane potential activation threshold, a fast inactivation, and small single-channel conductance [10] . By contrast, HVA L-and non-L-type channels require much stronger depolarization to reach activation threshold [11] , exhibit higher single-channel conductances, and show prolonged-channel opening in comparison to T-type channels [4, 12] . However, Ca v 1.3 L-type Ca 2+ channels were reported to exhibit mid-voltage activating characteristics under special physiological and electrophysiological conditions [12 -15] . Pharmacodynamically, HVA L-type Ca 2+ -channels are highly sensitive towards DHPs (e.g. nifedipine), phenylalkylamines (e.g. verapamil, gallopamil, devapamil) and benzothiazepines (e.g. diltiazem) [14, 16 -18] . Recently, ω-TRTX-Cc1a, derived from the venom of the tarantula Citharischius crawshayi (now Pelinobius muticus), turned out to be a potent and selective blocker of Ca v 1.2 and Ca v 1.3 Ca 2+ channels [19] . Experimental activators of L-type channels include BayK8644, FPL64176, PCA50941 and SZ(+)-(S)-202-791, none of which is however used in clinical application settings [20] .
Fig. (1). Structural buildup of voltage-gated Ca
2+ channel complexes. Voltage-gated Ca 2+ channels are composed of a central pore-forming and ion-conducting α 1 subunit as well a variable subset of auxiliary subunits, including α 2 δ, β and γ-subunits. The β-subunit is located intracellularly whereas the γ and δ subunits are placed within the plasma membrane. The α 2 subunit is covalently bound to the δ subunit via a disulfide bond and localized extracellularly. Both the Ca v -α 1 subunits as well as the auxiliary subunits are important drug targets (reprinted from [68] ).
spider Agelenopsis aperta preferentially targets Ca v 2.1 Ca 2+ channels. Other Ca v 2.1 blockers include ω-agatoxin IIIA, ω-agatoxin IVB, peptide toxins from the venom of the marine snail Conus geographus, i.e. ω-conotoxin MVIID, ω-conotoxin CVIB, ω-conotoxin CVIC, the spider toxin ω-phonetoxin IIA derived from Phoneutria nigriventer, DW13.3 extracted from the venom of the spider Filistata hibernalis and the scorpion venom toxin Kurtoxin [20, 22 -24] . Though widely used in basic science, none of these blockers has reached clinical application so far. Omega (ω)-conotoxin GVIA derived from Conus geographus preferentially blocks Ca v 2.2 Ca 2+ channels. Further Ca v 2.2 Ca 2+ channels blockers are ω-conotoxin MVIIA, ω-conotoxin CVIA, ω-conotoxin CVIB; ω-conotoxin CVIC, ω-conotoxin CVID, ω-conotoxin SO-3, DW 13.3 and Huwentoxin HWTX I [23 -25] . Omega (ω)-conotoxin MVIIC, a toxin from the venom gland of the marine snail Conus magnus, targets both Ca v 2.1 and Ca v 2.2 Ca 2+ channels [4, 26 -30] . In contrary, glycerotoxin from the venom of Glycera convoluta was shown to act as an activator of Ca v 2.2 Ca 2+ channels [31] . Although most naturally derived peptide toxins are predominantly of experimental interest and not yet applicable in humans, Ca v 2.1-2.3 VGCCs turned out to serve more and more as potential targets in epilepsy, pain treatment and other neurological diseases. Gabapentin, for example, inhibits Ca v 2.1 Ca 2+ channels via interaction with the α 2 δ auxiliary subunits (albeit non-selectively), and it can influence pain and epilepsy in humans [32] . Ziconotide (ω-conotoxin MVIIA, i.e. SNX-111), a toxin derived from the marine piscivorous snail Conus geographus, is likely to inhibit Ca v 2.2 Ca 2+ channels and is a potent drug in humans who turned out to be refractory or non-tolerant to opioids [29, 30] . The GABA B receptor agonist baclofen can strongly inhibit Ca v 2.1 and Ca v 2.3 whereas c-Vc1.1, a cyclized version of the analgesic α-conotoxin Vc1.1 acting through GABA B receptors, did not affect Ca v 2.1 but severely inhibited Ca v 2.3 Ca 2+ channels. These findings support the view that Vc1.1 inhibition of Ca v 2.3 VGCCs defines Ca v 2.3 Ca 2+ channels as a potential target in analgesic treatment [33] . For the LVA Ca v 3 Ca 2+ channels, a number of potential inhibitors have been evaluated, such as the tetraline derivative mibefradil and the scorpion toxin kurtoxin [34] . Other potential T-type Ca 2+ channel blockers include Protoxin-I or β-theraphotoxin-Tp1a (ProTx-I), NNC55-0396, ML-218 and pimozide. Recently, azetidinones and spiro-azetidines have been described as novel potential blockers of the T-type Ca 2+ channel Ca v 3.2 being of potential relevance for the treatment of neuropathic and inflammatory pain [35] . However, these potential T-type blockers have not reached clinical application so far. Diphenylalkylamine derivatives such as flunarizin or cinnarizin exhibit a non-specific blockade on VGCCs. Recently, new generation state-dependent T-type Ca 2+ channel antagonists such as TTA-P2 and TTA-A2 have been described which seem to interfere preferentially with inactivated T-type Ca 2+ channels [36] . Both state-dependent blockers exhibit analgesic effects in rodent models of pain. Z123212, a bi-targeting inhibitor of voltage-dependent Na + channels and T-type Ca 2+ channels exerts its analgesic effect by selectively targeting the slow inactivated state of the channels [37] . Notably, phase I clinical trials for the treatment of pain are currently performed for Z944, a state-dependent T-type channel inhibitor. Several pharmaceutical companies have focused their preclinical research on T-type Ca 2+ channels inhibitors and activators and the future will reveal if clinical drugs finally emerge from these efforts. Importantly, LVA [40] .
Within the last decade, Zn 2+ emerged to be one of the most important heavy metal ions within the CNS, to the extent that is was sometimes referred to as "the calcium of the twenty-first century" [41] . Both divalent trace metals, Zn 2+ and Cu 2+ , are implicated in a range of neurological disease states in humans that are characterized by alterations in neuronal excitability and/or neurodegeneration. Importantly, Zn 2+ is known to exert significant effects on epileptic activity and excitotoxicity. However, the role of Zn 2+ and Cu 2+ in epilepsy and excitotoxicity is complex, and partially ambivalent.
Whereas a number of studies illustrate that Zn 2+ is a potential ionic mediator of selective neuronal injury [42 -45] , others provide strong evidence that Zn 2+ is a powerful neuroprotector [41, 46 -53] . Similarly, Zn 2+ was reported to serve as both a proconvulsant [54] and anticonvulsant [55, 56] in humans and various animal models. These findings further support the apparent "Janus"-like behavior of Zn 2+ ions in modulating neurodegeneration and seizure susceptibility. However, most of these prima facie contradictory observations described in the literature are based on differences in voltage-and ligand-gated ion channel expression within various neuronal cell types investigated, e.g. hippocampal interneurons versus pyramidal cells. Following KA-induced limbic seizures, hippocampal interneurons exhibit a dramatic increase in cytosolic Zn 2+ -concentration and cell death which is supposed to be due to mitochondrial dysfunction [44] and activation of specific Zn 2+ -signaling pathways [57] . Hippocampal interneurons were further reported to express Ca 2+ -permeable AMPA-receptors [58] , and to release Zn 2+ from mitochondria and other intracellular stores or metallothioneins [44] . Zn 2+ -levels turned out to be higher in interneurons compared to hippocampal pyramidal cells [59] due to differences in Ca 2+ -AMPA-receptor expression, Ca 2+ -buffering systems and differences in mitochondrial metabolism [60] . Compared to interneurons, CA3 pyramidal cells display only a moderate increase in internal Ca 2+ -levels after KA treatment [59] . Findings of Zn 2+ -release, intracellular Zn 2+ -accumulation and its effects on KA-seizure susceptibility and excitotoxicity are rather divergent as well. Whereas extracellular chelation of Zn 2+ in one study neither affected hippocampal excitability nor seizure-induced cell death [61] , studies by Takeda et al. illustrated that Zn 2+ can clearly attenuate KA-induced limbic seizure activity and concomitant neurodegeneration in the CA3 region, or induce inverse effects, when being chelated extracellularly [46 -53, 62] . Thus, by complex modulation of the inhibition -excitation balance involving VGCCs, Zn 2+ -homeostasis is crucial for both the induction of and the prevention of hyperexcitability-related seizure development and neurodegeneration. Most importantly, Zn 2+ ions can exhibit not only different modulatory effects on numerous voltage-and ligand-gated ion channels such as VGCCs, but also enter cells via different channels including VGCCs, AMPA-, NMDA-and KA-receptors, particularly when neurons exhibit repetitive activation or hyperexcitability [41, 45, 63] . Thus, both Ca 2+ and Zn 2+ can serve as synaptic or transsynaptic second messengers with extracellular diffusion, e.g. spillover effects at mossy fibre terminals enabling complex heterosynaptic modulation. In line with these findings, synaptically released Zn 2+ can effectively inhibit longterm potentiation (LTP) presynaptically at the mossy fiber synapse [64] . These findings directly corroborate the crucial role of HVA Ca v 2.3 R-type Ca 2+ channels, serving as a Zn 2+ target in presynaptic LTP [38, 65, 66] as will be outlined below (Fig. 2) .
In drug research and development there is a strong need for new medical entities, i.e. first-in-class medicines that preferentially target individual Ca 2+ channel entities. Arranz-Tagarro et al. [20] [6, 69] and might also serve as targets in future drug research and development.
The Ca v β 3 subunit for example determines the plasma membrane density of the pore-forming Ca v 2.3 α 1 -subunit. Four leucine residues in Ca v β 3 form a hydrophobic pocket surrounding key residues in the Ca v 2.3 α 1 -domain. This interaction seems to play an important role in conferring Ca v β-induced modulation of the protein density of Ca v α 1 -subunits in Ca v 2 channels [70] . In this context, interaction partners of VGCCs turned out to be most relevant in drug discovery and development, particularly in the field of epilepsy. Recently, an exceptional study on quantitative proteomics of Ca v 2 channel nano-environments, using knockout-controlled multiepitope affinity purifications together with high-resolution quantitative mass spectroscopy was carried out to unravel the molecular players in local subcellular signalling [71] . About 200 proteins have been identified that clearly differ in abundance, stability of assembly and preference for the individual Ca v 2 subunits. These potential interaction partners included kinases and phosphatases, cytoskeleton proteins, enzymes, SNAREs, modulators and small GTPases, various G-protein coupled receptors, ion channels and transporters, adaptors, extracellular matrix proteins, cytomatrix components, protein trafficking components and additional proteins of yet unknown function. [75 -78] . Both HVA and LVA Ca 2+ channels are predominant mediators of internal Ca 2+ elevation during most epileptiform activity [75, 79] . In hippocampal neurons it has been reported that the density of Ca 2+ current was up-regulated during ictogenesis / epileptogenesis [80] and inhibition of VGCCs substantially depressed epileptiform activity [81, 82] . On the cellular electrophysiological level, Ca 2+ channels were proven to be of central importance in mediating potential ictiform / epileptiform activity, such as afterdepolarization (ADP), plateau potentials (PP) and exacerbation of low-threshold Ca 2+ spikes (LTCS) / rebound burst firing thus mediating seizure initiation, propagation and kindling [34, 83 -86] . In addition, VGCCs exert major effects in excitotoxicity and neurodegeneration contributing to the devastating pathophysiology of human neuronal diseases associated with neurodegeneration [87 -89] . Therefore, pharmacological modulation of VGCCs is a promising approach in functional interference with seizure activity, excitotoxicity and neurodegeneration [90 -96] . As outlined below, many studies regarding the involvement of VGCCs in ictogenesis and epileptogenesis were carried out on HVA Ca v 2.1 and LVA Ca v 3 type Ca 2+ channels. However, within the last years, a specific focus has been on the unexpected role of Ca v 2.3 R-type VGCCs in the field of epilepsy.
Ca

2+ CHANNELS IN ICTOGENESIS AND EPILEPTOGENESIS
WHAT MAKES Ca v 2.3 R-TYPE Ca 2+ CHANNELS SPECIAL?
The Ca v 2.3 R-type Ca 2+ channel exhibits a complex histological and cellular distribution pattern with Ca v 2.3 being expressed in the peripheral and central nervous system (CNS), the endocrine [97, 98] , cardiovascular [99 -101] , reproductive [102 -105] , and gastrointestinal system [106] . Additionally, Ca v 2.3 is of central relevance in the developing lung [107] and sensing organs such as the inner ear and organ of Corti [108] . In the last 15 years researchers have gained tremendous insight into the functional role of Ca v 2.3 Ca 2+ channels based on the generation of Ca v 2.3 deficient mice. Within the CNS, Ca v 2.3 VGCCs are involved in presynaptic / postsynaptic plasticity and neurotransmitter release [65, 66] . Additionally, Ca v 2.3 Ca 2+ channels were shown to be engaged in the control of pain behavior [109] , the physiology of fear [110] and myelinogenesis [111] . Interestingly, Ca v 2.3 VGCCs are also involved in the semaphorin 3A mediated conversion of axons to dendrites and the control of neuronal identity during nervous system development [112] . Furthermore, Ca v 2.3 Ca 2+ channels seem to exhibit a protective function in ischemic neuronal injury [113] and contribute to vasospasms following subarachnoid hemorrage in humans [114] . Ca v 2.3 R-type VGCCs were also thought to play a crucial role in mediating analgesic opioid effects and underlying pain pathways. Although it remains unknown to a large extend whether single-nucleotide polymorphisms of the human CACNA1E gene encoding Ca v 2.3 VGCCs affect the analgesic effects of opioids, there is increasing evidence of a link between CACNA1E gene polymorphisms and fentanyl sensitivity [115] . Besides Ca v 1.2, the Ca v 2.3 VGCC is also expressed in colonic primary sensory neurons and was reported to be of major importance in visceral inflammatory hyperalgesia [116] . Inhibition of Ca v 2.3 VGCCs by eugenol was also shown to contribute to its analgesic effect [117] . The expression of Ca v 2.3e as the main R-type VGCC isoform in nociceptive DRG neurons also points to a potential target for pain treatment, e.g. in the trigeminal and spinal cord system [118, 119] [124] and it is also expressed at the neuromuscular junction [125] . At the presynaptic site, a minor fraction of Ca v 2.3 VGCCs is are localized to the active zone of the vesicle fusion machinery and thus functionally contributes to neurotransmission [123] . A dominant fraction however, is localized more peripheral in the synapse responsible for synaptic plasticity, e.g. long-term potentiation (LTP) [66] . In addition, it should be noted that Ca v 2.3 R-type VGCCs are homogenously expressed on the cell soma and the dendritic arbor. The dendritic expression pattern is highly complex and only present in certain CNS nuclei and specific cell types, such as CA1 neurons. The highly organized spatial distribution pattern of Ca v 2.3 Ca 2+ channels with predominant expression in the proximal or distal dendrites clearly differs from other HVA VGCCs [126] . Functionally, Ca v 2.3 was reported to underlie the generation of Ca 2+ -dependent APs. The latter are conducted along the ramified dendritic arbor which serves an important entry site of Ca 2+ and crucial factor in neural electrogenesis [127] . This characteristic somatatodendritic function of Ca v 2.3 VGCCs is likely to be involved in a number of characteristic ictiform / epileptiform electrical phenomena. Ca v 2.3 R-type Ca 2+ channels were considered to be unique as they turned out to be resistant to most Ca 2+ channel blockers. In 1998 however, the spider peptide toxin SNX-482, derived from the venom of the tarantula Hysterocrates gigas (homologous to the spider peptides grammatoxin S1A and hanatoxin), was demonstrated to be a selective Ca v 2.3 Ca 2+ channel antagonist at low nanomolar concentrations (IC 50 = 15-30 nM) [128] .
Recently however it turned out that SNX-482 also dramatically reduces A-type K + currents in mouse dopaminergic neurons from the substantia nigra pars compacta. Patch-clamp studies on K v 4.3 stably transfected HEK293 cells revealed an IC 50 < 3nM which indicates a substantially higher potency than for SNX-482 inhibition of Ca v 2.3 Ca 2+ channels [129] . Thus, caution has to be exercised when interpreting SNX-482 antagonistic effects on cells and neural circuits where these channels are actually expressed. Ca v 2.3 blocking effects were also reported for DW 13.3, the Phoneutria (Ctenus) nigriventer (Brazil armed spider) toxin ω-ctenitoxin-Pn2a including ω-PnTx3-3, ω-PnTx3-6 and ω-phonetoxin IIA [20] . In addition, Ca v 2. clearly based on the chelating effect and mechanistically distinct from the activation of intracellular signal transduction cascades [134] . Glutamate effects on Ca v 2.3 are exerted from the extracellular space and although the trace metal binding character has been documented before [135] it was not considered to be physiologically relevant until now.
Importantly, it has never been mentioned before that trace amounts of divalent heavy metals that often contaminate external solutions [130, 136] (Fig. 2) . It should further be noted that extracellular acidification can decrease Ca 2+ current amplitude and results in a depolarizing shift in the activation potential (V a ) of VGCCs. These effects hold true for all VGCC including Ca v 2.3, but differences occur between individual VGCC entities and the underlying molecular mechanisms remain unknown. Alterations of Ca 2+ current amplitude effectuated by extracellular acidification or alkalinisation were shown to be of higher importance for Ca v 2.3 R type VGCCs than for Ca v 2.1 P/Qtype channels for example [137] .
MODULATION OF Ca v 2.3 VGCCS VIA DIFFERENT RECEPTORS AND SIGNALING CASCADES
A number of Ca v 2.3 splice variants have been described [138] and this diversity is likely to be potentiated by coassembly with different auxiliary subunits such as α 2 δ, β, and γ. The Ca v 2.3 VGCC is modulated biochemically by interconversion, i.e. phosphorylation and dephosphorylation. These two processes are of central relevance as they can alter fundamental electrophysiological properties of the channel and are related to the induction and perseveration of epileptiform burst activity in neurons [139] [140, 141] . This mechanism represents a positive feedback based on the presence of exon 19 that represents an arginine rich insert 1 in the cytosolic II-III loop [138] . In consequence, Ca v 2.3e R-type Ca 2+ channels lacking exon 19 encoded insert 1, exhibit only residual phorbol ester mediated stimulation which is however still significant. This view is supported by the observation that coexpression of PKC α with Ca v 2.3e results in similar kinetics of inactivation and recovery as obtained for the full length II-III loop splice variant Ca v 2.3d. These findings suggest that the expression pattern of Ca v 2.3 splice variants in different brain regions is of significant relevance for neuronal mechanisms underlying neuroprotection, icto-/epileptogenesis and seizure propagation [94] . Importantly, a positive feedback mechanism by Ca 2+ influx was also reported for L-type Ca 2+ channels and is mediated through Ca 2+ /calmodulin kinase II [142] . At elevated cytosolic Ca 2+ concentrations however, a prominent Ca 2+ -dependent inactivation renders the channel activity to further increase [143] . PKC-mediated protein phosphorylation is of major physiological relevance, mediating intracellular messengers and hormonal effects. VGCCs serve as effectors in numerous regulatory neurotransmitter and hormonal pathways initiated by G-proteins. This G-protein mediated regulation of VGCCs can either be indirect via second messengers and/or protein kinases or direct via physical interaction between G-protein subunits and the Ca v α 1 -subunit. Functional studies elicited that G-protein interaction reversibly inhibits neuronal non-L type Ca 2+ -channels. Peak current amplitude is reduced and activation kinetics is slowed. The effects of the hetereotrimeric G-proteins on VGCC are well described for the G βγ dimer [144, 145] , whereas the role of G α is yet not well understood. There is strong evidence that G βγ directly interacts with the I-II linker of the Ca v α 1 -subunit [146, 147] . Furthermore, the N-terminus of Ca v 2 α 1 subunits also seems to be involved in G-protein coupled modulation [148] including Ca v 2.3. The G βγ interaction site within the I-II linker partially overlaps the AID (α 1 -interacting domain) where β subunits bind. This observation suggests a physical competition between the agonistic β-subunits [148, 149] and the antagonistic effects of G βγ [150] . Interestingly, it turned out that G βγ exhibits inhibitory effects on LVA Ca v 3 T-type Ca 2+ -channels via interaction with the II-III-loop [151] . There are further hints of a sophisticated interdependence between G-protein pathways and PKC as activation of PKC antagonizes adjacent receptor-mediated G-protein inhibition of VGCC [147, 152] . Accumulation of internal Ca 2+ at low concentrations leads to tonic activation of Ca v 2.3d resulting in enhanced responses, i.e. slowed inactivation and accelerated recovery from inactivation [140] . It has been reported by Dietrich et al. [66] [159] and it was speculated that this might influence synaptic transmission during brain development and contribute to pathophysiological processes when axon regeneration and growth cone kinetics are impaired [159] .
Ca v 2.3 TYPE VGCCS IN CONVULSIVE SEIZURE ACTIVITY
Aberrant burst activity is a typical feature of neuronal epileptiform activity. Each cellular burst is based on a slow, persistent depolarization, the so-called PP [160] which can last up to seconds [161, 162] . A PP is regenerative, spike dependent and is mediated by the summation of depolarizing APs [163, 164] . In addition, internal Ca 2+ levels attain a plateau that is typically 4200 nM above rest and reached after several seconds of activity. However, the PP generally collapses soon, once the electrical activity has ceased and the membrane repolarizes again [163, 164] . As regards PP termination, it has been suggested that an increase of internal Ca 2+ and the subsequent activation of a Ca 2+ -dependent K + -mediated afterhyperpolarisation (AHP) might account for this phenomenon [165, 166] . Besides, a shift from Ca 2+ -dependent facilitation to Ca 2+ dependent inactivation of VGCCs with increased internal Ca 2+ levels might also be involved. Generally, PPs and ADP are common electrophysiological phenomena in different neuronal cell entities in different brain regions such as spinal and brainstem motor neurons, spinal interneurons, dorsal horn neurons, subicular and entorhinal cortical cells, subthalamic nucleus neurons, suprachiasmatic neurons, striatal cholinergic neurons and hippocampal pyramidal cells [167] . Nevertheless, the entire voltage-and ligand-gated ion channel armamentarium underlying PP and ADP generation is still not fully understood. Recent studies more and more suggest that Ca v 2.3 VGCCs are potent players in PP and ADP generation thus serving an important role in ictogensis [168 -175] .
Importantly, one has to consider that these data were recorded from various tissue preparations from different species and that dihydropyridines involved in these studies exert complex action on VGCCs. Experimental conditions, such as neuronal membrane potential or penetration depth of various VGCC blockers in CNS slices can severely modulate electrophysiological results [176 -178] .
Various neurological and cardiovascular studies have suggested that Ca v 1.3 could mediate both a low-threshold and low-dihydropyridine sensitive L-type Ca 2+ current [12, 15] . In consequence, Ca v 1.3 was speculated to be involved in PP generation in different neuronal cell types. Whereas the electrophysiological behavior of LVA Ca v 1.3 Ca 2+ channels has been described recently [12, 14] , Ca v 2.3 had already been known to exhibit low-to mid-voltage activated activity based on both activation and steady-state inactivation kinetics prominent at relatively negative membrane potentials [99, 167, 179 -183] . In addition, Ca v 2.3 R-type Ca 2+ channels were shown to contribute to sustained PPs and ADPs in hippocampal CA1 neurons with the latter known to enhance neural excitability and epileptogenicity [85, 184] . Studies by Fraser and MacVicar [185] and Fraser et al. [186] demonstrated that carbachol mediated cholinergic stimulation of CA1 neurons causes slow ADP and long lasting PP both of which resemble epileptiform activity. In general, activation of the cholinergic system is a well-known approach to induce limbic seizures both in vitro and in vivo [187 -190] . Importantly, PPs are important electrophysiological phenomena in ictogenesis mediated by Ca 2+ influx through VGCCs. They are modulated upon muscarinic receptor activation and mediate activation of guanylate cyclase activity and subsequent increase in cGMP [191] (Fig. 3) . Ca v 2.3 R-type VGCCs were proven to be responsible for Ca 2+ influx in dendritic spines, e.g. of CA1 neurons [192] and it was further depicted that a reduction of R-type Ca 2+ current reduces the accumulation of postsynaptic [Ca 2+ ] i , particularly following recurrent synaptic activation [193, 194] . Notably, stimulation of metabotropic muscarinic receptors via carbachol for example results in inhibition of L-, N-, and P/Q-type VGCCs [195 -197] . In contrast, R-type Ca 2+ current is significantly enhanced [198 -200] . Topiramate, an AED drug that was shown to block carbachol-induced PPs in subicular bursting cells [201] was used by Kuzmiski et al. [85] to directly prove that topiramate can dampen the generation of PPs by inhibiting R-type VGCCs. Pharmacodynamically, topiramate has a multi-target character interacting with, e.g. voltage-gated sodium channels, VGCCs and AMPA/kainite receptors or GABA(A) receptors [85, 202] . Kuzmiski et al. [85] currents in rat CA1 pyramidal neurons following selective blockage of N-, P/Q-, and L-type Ca 2+ currents [84] . Hippocampal pyramidal neurons are known to highly express postsynaptic M 1 and M 3 receptors [204, 205] which are Gα q/11 coupled. Activation of M 1 /M 3 and attached G-proteins results in synthesis of DAG and IP3 following PLC activation. DAG can activate Ca 2+ -independent group II PKCs, most likely PKCδ [84] . This findings goes together with the observation that R-type Ca 2+ currents are inhibited upon muscarinic receptor stimulation in CA1 neurons once PKC is inhibited. This phenomenon is due to the activation of pertussis toxin-sensitive G-protein-coupled M 2 /M 4 receptors as well as G βγ subunits [157, 158] . The hippocampal ictogenic potency of Ca v 2.3 VGCCs is also confirmed by the observation that mice lacking the M 1 receptor display reduced seizure susceptibility following pilocarpine adminstration [206] . One should consider that etiopathogenetic mechanisms of ictogenesis and/or epileptogenesis can also include other voltage-dependent Ca 2+ conductance as well [207] . During early stages of epileptogensis, Hendriksen et al. [208] observed a significant increase in Ca v 2.1, Ca v 1.3-and particularly Ca v 2.3 α 1 mRNA levels in the hippocampal compared to control animals in an electrical stimulation model [208] .
Within the last decade there has been an increasing number of reports that directly link VGCCs to specific epilepsy entities in humans as well. Indeed, a number of mutations within the ion-conducting Ca v α 1 subunits and the auxiliary subunits (β, α 2 δ, and γ) of VGCCs were shown to be involved in convulsive and non-convulsive seizure activities in humans. These include i.a. childhood absence epilepsy (CAE) or juvenile myoclonus epilepsy (JME). Mutations in the HVA Ca v 2.1 VGCC for example were detected in patients suffering from absence epilepsy, episodic ataxia type 2 (EA2), and spinocerebellar ataxia type 6 (SCA6 hippocampal ictogenesis but also complex rhythm generation in the septohippocampal network [210] . It was shown that Ca v 2.3 VGCCs contribute to the genesis of atropine-sensitive type II. Urethane-induced atropine-sensitive type II theta oscillations are induced by muscarinic signaling via Gα q/11 , PLCβ 1/4 , InsP 3 , DAG and PKC (Fig. 3) [210] . Unlike PLC β1 deletion, ablation of Ca v 2.3 does not result in a total abolishment of type II theta oscillations. However, the temporal characteristics of theta distribution, i.e. theta architecture was significantly altered upon Ca v 2.3 deletion [210] . Thus, Ca v 2.3 VGCC are also of tremendous in relevance septohippocampal synchronization associated with theta oscillation [210] . 
Ca v 2.3 VGCCS IN NON-CONVULSIVE SEIZURE ACTIVITY
Behaviorally, typical absence epilepsy is the prototype of non-convulsive seizure activity. It is characterized by a sudden onset and termination of paroxysmal loss of consciousness that is accompanied by bilateral synchronous spikewave discharges (SWD). The frequency of these SWD turned out to be species-specific [211] . It has been shown several years ago that the TC circuitry, particularly the contribution of the ventrobasal thalamus and the reticular thalamic nucleus (RTN) are functionally involved in the initiation and propagation of absence seizures [212] . In addition, also extrathalamocortical structures, e.g. the reticular formation, the pedunculopontine tegmental nucleus, the laterodorsal tegmental nucleus, the basal nucleus of Meynert, the raphe nuclei, the locus coeruleus and cerebellar structures are functionally connected to the TC circuitry. Interestingly, brain structures like hippocampus or cerebellum that are classically not known to be involved in the generation of absence SWDs in fact also participate in the development of the absence epilepsy phenotype [213] . On the pathophysiological level, TC dysrhythmia is assumed to be the substrate of SWDs. Electrophysiologically, thalamic relay neurons but also others have the unique capability to shift between different functional states, i.e. the tonic mode, the intermediate mode and the burst firing mode. These different modes strongly regulate transmission of external information to the cortex [214] . The tonic firing mode is typical of stages of high vigilance. When ascending activity originating from deeper brain structures decreases, thalamic relay neurons re-and hyperpolarize. They first exhibit the intermediate mode and finally display rebound burst firing. A number of voltage-and ligand-gated channels involved have been characterized including hyperpolarization and cyclicnucleotide gated, non-specific cation channels (e.g. HCN2, HCN4) and LVA Ca v 3.1-3.3 T-type Ca 2+ channels that can trigger LTCSs with superimposed bursts of conventional Na + /K + APs. Rebound burst firing can be terminated by both voltage-and Ca 2+ -activated current entities, e.g., I A and I K(Ca2+) . Rebound burst firing in the TC circuitry is characteristic of low vigilance as holds true for slow wave sleep (SWS). Furthermore, reinforced oscillatory activity accompanied with intensive rebound burst firing of RTN and thalamic relay neurons is of central importance in the etiopathogenesis of absence epilepsy. Within the TC network, oscillatory activity is substantially triggered and sustained by the RTN which helps to control information gating and transfer from the periphery over the thalamus to the cortex. The shellshaped RTN is strategically placed lateral to the ventrobasal thalamic relay nucleus and exerts inhibitory GABAergic activity on RTN cells themselves as well as on thalamic relay neurons [212] . Interestingly, a number of single-mutation mouse models of absence epilepsy have been described most of which related to genetic ablation of VGCCs. This underlines the critical role of VGCCs in absence epileptogenesis. In particular, HVA Ca v 2.1 and Ca v 3 LVA T-type Ca 2+ channels were proven to be of central relevance in this field. For example, the Ca v 3.1 VGCC knock-out mouse model was reported to display resistance to absence seizures and a lack of burst firing in TC relay neurons [215] . In addition, Ca v 3.1 -/-mice exhibited altered sleep architecture and a clear lack of delta waves [216] . The Ca v 3. [219] . Besides, Ca v 3.1 VGCCs might be involved in movement disorders such as paroxysmal dyskinesia and ataxia [220, 221] . Summing up, enhanced T-type Ca 2+ currents in various cellular components of the TC network were shown to be a critical phenomenon in absence epileptogenesis although it does not seem to be a must [219] . Clearly, Ca v 3 T-and Ca v 2.1 P/Q-type VGCCs are not the only electrophysiological players within the TC circuitry. Gabaergic interneurons of the cortex and the RTN as well as extrathalamocortical structures were proven to express Ca v 2.3 VGCCs [96, 179, 222 -225] . A lot of studies as regards the role of Ca v 2.3 VGCCs in absence epileptogenesis were carried out in Wistar Albino Glaxo rats (WAG/Rij) and Genetic Absence Epilepsy Rats from Strasbourg (GAERS). In the latter, increased T-type Ca 2+ currents in reticular thalamic neurons have been reported [226] and subsequently also changes in Ca v 3.1 and Ca v 3.2 Ca 2+ channel expression in related thalamic nuclei, i.e. the adult ventroposterior thalamic nuclei and the RTN, respectively [223] . Importantly, de Borman et al. [222] and Lakaye et al. [213] described a prominent decrease of Ca v 2.3 VGCC in two extrathalamocortical brain structures in GAERS, the brainstem and the cerebellum both of which project to the TC circuitry, capable of modulating its oscillatory activity [227 -229] . In addition, the WAG/Rij rat model of absence epilepsy displays altered VGCC expression as well. Development of SWDs in WAG/Rij rats goes together with an enhanced expression of Ca v 2.1 VGCC in the RTN. Interestingly, van de Bovenkamp-Janssen et al. [224, 225] tonic mode of action [233] . Recently however, Zaman et al. [86, 234] [192, 235 -237] as well as in epileptogenicity [238] .
Given the cellular electrophysiological findings and absence seizure study results from [86] , one might speculate that SWS is reduced in Ca v 2.3 -/-mice. However, we observed an opposite effect [239] . VGCCs are expressed in a number of extra-thalamocortical structures, such as the mesopontine REM-NREM modulators (the locus coeruleus, the dorsal raphe nuclei, the pedunculopontine, and the laterodorsal tegmental nuclei), the diencephalic sleep onset controllers (hypothalamic nuclei including the ventrolateral/lateral preoptic region and the tuberomammillary basal forebrain), the cerebellum, the basal ganglia and the hippocampus [94, 96] . These structures are known to project to the TC circuitry and substantially modify its activity via different neuromodulators, e.g., noradrenalin, histamine, serotonin (5-HT), and acetylcholine [92, 211, 241] . Other important Ca v 2.3 expressing structures include the suprachiasmatic nucleus involved in the regulation of the circadian rhythm and also sleep architecture [242, 243] to the fact that a valid model of TC rhythmicity needs to include input also from extrathalamocortical structures. In conclusion, there is strong evidence that Ca v 2.3 VGCCs play a primary role in SWS, the etiology and pathogenesis of absence epilepsy and SWD generation.
Ca v 2.3 R-TYPE VGCC CHANNEL MODULATION AND ITS CLINICAL CONSEQUENCES
VGCCs are important targets for numerous AEDs [139, 244, 245] . Most AEDs were shown to inhibit HVA or LVA Ca 2+ channels others than Ca v 2.3 VGCCs. Based on the findings described above, there is striking evidence that Ca v 2.3
VGCCs can serve as targets in convulsive and non-convulsive seizure pharmacotherapy. Lamotrigine (LTG) for example is a multi-target AED for the treatment of typical absence seizures and the Lennox-Gastaut syndrome [246, 247] . Pharmacodynamically, it acts via inhibition of both voltage-gated Na + and Ca 2+ channels [248] . anticonvulsant efficacy and could thus prevent neurons from hyperexcitability and excitotoxicity [79] . Notably, sipatrigine or 202W92 can also inhibit Ca v 2.3 VGCCs with IC 50 values of 10 μM which is within therapeutically relevant brain concentrations of 20-100 μM for sipatrigine and 56 μM for 202W92. Furthermore, both sipatrigine and 202W92 exhibited neuroprotective effects in various animal models of ischemia [251, 252] and displayed anticonvulsant efficacy in both genetically epilepsy-prone rats and DBA/2 audiogenic mice [230, 253] . Importantly, McNaughton et al. [254] have characterized other potential Ca v 2.3 blockers that might be relevant in antiepileptic treatment, i.e. carbonic anhydrase inhibitors. The latter include for example ethoxyzolamide, acetazolamide and dichlorphenamide. Carbonic anhydrase inhibitors have numerous clinical applications, e.g. induction of diuresis, ocular hypertension relief and treatment of altitude sickness [255, 256] . However, epidemiological approaches also suggest their efficacy in patients suffering from absence epilepsy [255] . Ethoxyzolamide inhibited Ca v 2.3 mediated R-type Ca 2+ current by 66-74% at 10 μM. On the other hand, dichlorphenamide (10 μM) which is used for treatment of generalized epilepsies resulted in a 24-76% reduction of R-type current [254] . Importantly, topiramate, a standard AED nowadays shares structural similarities with carbonic anhydrase inhibitors and indeed also exerts remaining inhibitory action on carbonic anhydrases. Topiramate had already been reported to inhibit L-type Ca 2+ currents [257] . Recently however, it was also proven [85, 254] Given the functional involvement of Ca v 2.3 VGCCs in the etiopathogenesis of both convulsive and non-convulsive seizures but also sleep (patho)physiology, future development of highly specific Ca v 2.3 Ca 2+ channels blockers will be of tremendous pharmacotherapeutic relevance and a benefit for patients. 
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